Stock Events

Stock Events

Definium Therapeutics 

€19.75
915
+€0.75+3.95% Today

Statistics

Day High
19.8
Day Low
18.9
52W High
20.1
52W Low
4.7
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q4 2025
Next
-0.43
-0.42
-0.42
-0.41
Expected EPS
-0.41997796731
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MMQ0.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Compass Pathways
CMPS
Mkt Cap1.22B
Compass Pathways operates in the psychedelic medicine space, focusing on psilocybin therapy for depression, directly competing with Mind Medicine's psychedelic-based treatments.
AtaiBeckley
ATAI
Mkt Cap1.52B
ATAI Life Sciences is a biotech company with a focus on psychedelic and non-psychedelic compounds for mental health, making it a direct competitor in the psychedelic medicine market.
GH Research
GHRS
Mkt Cap1.42B
GH Research is developing a novel therapeutic approach for mental health disorders using 5-MeO-DMT, competing in the same space as Mind Medicine's psychedelic-based treatments.
Nuveen Municipal Income
NUMI
Mkt Cap0
Numinus Wellness is involved in the development of psychedelic therapies, including psilocybin and MDMA, positioning it as a competitor in the psychedelic medicine industry.
Revive Therapeutics
RVVTF
Mkt Cap11.33M
Revive Therapeutics is exploring the use of psychedelics for the treatment of mental illness and addiction, competing in the same therapeutic space as Mind Medicine.
TripAdvisor
TRIP
Mkt Cap1.35B
Red Light Holland is focused on the production, growth, and sale of a premium brand of magic truffles, entering the broader market of psychedelic substances that Mind Medicine is also targeting.
Noveris Health Sciences
MYCOF
Mkt Cap48.92M
Mydecine Innovations Group is a biotech company focusing on the development of psychedelic therapies, making it a competitor in the emerging field of psychedelic medicine.

About

Definium Therapeutics, Inc. is a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Show more...
CEO
Mr. Robert Barrow
Employees
74
Country
Canada
ISIN
CA24477V1058

Listings

STU
DE
MMQ0.STU
MU
DE
MMQ0.MU
F
DE
MMQ0.F
XNAS
US
DFTX

0 Comments

Share your thoughts

FAQ

What is Definium Therapeutics stock price today?▼
The current price of MMQ0.STU is €19.75 EUR — it has increased by +3.95% in the past 24 hours. Watch Definium Therapeutics stock price performance more closely on the chart.
What is Definium Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Definium Therapeutics stocks are traded under the ticker MMQ0.STU.
When is the next Definium Therapeutics earnings date?▼
Definium Therapeutics is going to release the next earnings report on May 07, 2026.
What were Definium Therapeutics earnings last quarter?▼
MMQ0.STU earnings for the last quarter are -0.43 EUR per share, whereas the estimation was -0.41 EUR resulting in a -5.44% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Definium Therapeutics have?▼
As of May 06, 2026, the company has 74 employees.
In which sector is Definium Therapeutics located?▼
Definium Therapeutics operates in the Health & Wellness sector.
When did Definium Therapeutics complete a stock split?▼
Definium Therapeutics has not had any recent stock splits.
Where is Definium Therapeutics headquartered?▼
Definium Therapeutics is headquartered in New York, Canada.